| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CLBS-12 | CLBS-12 | Phase 2 Clinical | Caladrius Biosciences Inc | Atherosclerosis; Ischemia; Thromboangiitis Obliterans | Details |
| Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) | Phase 2 Clinical | Ucla Biomedical Library | Adenosine deaminase deficiency | Details | |
| CD34+ bone marrow stem cells (University of California) | Phase 2 Clinical | The University Of California Davis | Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion; Retinitis Pigmentosa | Details | |
| Autologous peripheral blood stem cell therapy (CellProthera) | Phase 2 Clinical | Cellprothera | Myocardial Infarction | Details | |
| CD34 stem cell therapy (LA Childrens Hospital) | Phase 2 Clinical | Children'S Hospital Of Los Angeles | Heart Failure; HIV Infections | Details | |
| Stem cell therapeutics (ExCellThera) | ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 | Phase 2 Clinical | Excellthera Inc | Leukemia, Myeloid, Acute | Details |
| Lentiviral vector transduced CD34+ cells Therapy | Phase 2 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Granulomatous Disease, Chronic | Details | |
| Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System) | HSC-100 | Phase 1 Clinical | Icahn School Of Medicine At Mount Sinai, Tatcitus Therapeutics | Hematologic Neoplasms; Hodgkin Disease; Leukemia; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| shRNA-Modified CD34 Cell Therapy | KL-AI20 | Phase 1 Clinical | Kanglin Biotech (Hangzhou) Co Ltd | HIV Infections | Details |
| Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) | Phase 1 Clinical | University Health Network (Uhn) | Fabry Disease | Details | |
| Autologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd) | GMCN-508A | Phase 1 Clinical | Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd | alpha-Thalassemia | Details |
| Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center) | Phase 1 Clinical | German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-CD34 mab-sirolimus (OrbusNeich) | Approved | Orbusneich | Coronary Restenosis | Orbusneich | 2013-01-01 | Coronary Artery Disease; Coronary Restenosis | Details |